Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-02-08
2011-12-13
Habte, Kahsay T (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S552000
Reexamination Certificate
active
08076322
ABSTRACT:
Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure:or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein n1, n2, n3, n4, A, B, D, E, G, Y, Z, R1and R2are defined herein.
REFERENCES:
patent: 3826643 (1974-07-01), Diehl et al.
patent: 5488064 (1996-01-01), Sher
patent: 5491134 (1996-02-01), Sher et al.
patent: 5541204 (1996-07-01), Sher et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5770615 (1998-06-01), Cheng et al.
patent: 5776983 (1998-07-01), Washburn et al.
patent: 6043265 (2000-03-01), Murugesan et al.
patent: 6566384 (2003-05-01), Owen et al.
patent: 7928230 (2011-04-01), Wacker et al.
patent: 2003/0181420 (2003-09-01), Bayne et al.
patent: 2005/0080111 (2005-04-01), Bayne et al.
patent: 2005/0245515 (2005-11-01), Dehmlow et al.
patent: 2006/0155128 (2006-07-01), Jones et al.
patent: 2006/0292073 (2006-12-01), Goodman et al.
patent: 2009/0018055 (2009-01-01), Fevig et al.
patent: 2009/0023702 (2009-01-01), Wacker et al.
patent: 1 338 651 (2003-08-01), None
patent: WO 96/38144 (1996-12-01), None
patent: WO 97/12613 (1997-04-01), None
patent: WO 97/12615 (1997-04-01), None
patent: WO 99/26659 (1999-06-01), None
patent: WO 00/01389 (2000-01-01), None
patent: WO 00/39102 (2000-07-01), None
patent: WO 02/02519 (2002-01-01), None
patent: WO 2004/065380 (2004-08-01), None
patent: WO 2004/076413 (2004-09-01), None
patent: WO 2004/089885 (2004-10-01), None
patent: WO 2005/007647 (2005-01-01), None
patent: WO 2005/007658 (2005-01-01), None
patent: WO 2005/025504 (2005-03-01), None
patent: WO 2005/089786 (2005-09-01), None
patent: WO 2005/121121 (2005-12-01), None
patent: WO 2006/067532 (2006-06-01), None
patent: WO 2006/083491 (2006-08-01), None
Chalmers (TiPS vol. 17, pp. 166-172 Apr. 1996).
Wermuth, C.G. et at, Chapter 31: “Designing Prodrugs and Bioprecursors I: Carrier Prodrugs”, The Practice of Medicinal Chemistry, Academic Press Limited, publ., Wermuth, C.G., ed., pp. 671-696 (1996).
Young, S.D. et at, “L-743,726 (DMP-266): a Novel, Highly Potent Nonnucleoside Inhibitor of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase”, Antimicrobial Agents and Chemotherapy, vol. 39, No. 12, pp. 2602-2605 (1995).
Chalmers (TiPS vol. 17, pp. 166-172, Apr. 1996).
Donetti, A. et al., “(Imidazolylphenyl)formamidines. A Structurally Novel Class of Potent Histamine H2Antagonists”, J. Med. Chem., vol. 27, No. 3, pp. 380-386 (1984).
Gomtsyan, A. et al., “Design, Synthesis, and Structure-Activity Relationship of 6-Alkynylpyrimidines as Potent Adenosine Kinase Inhibitors”, J. Med. Chem., vol. 45, No. 17, pp. 3639-3648 (2002).
Ahrén, B., “Autonomic regulation of islet hormone secretion—Implications for health and disease”, Diabetologia, vol. 43, pp. 393-410 (2000).
Arbeeny, C. et al., “The Metabolic Syndrome: From Pathophysiology to Novel Treatment Strategies”, Curr. Med. Chem.—Imm., Endoc. & Metab. Agents, vol. 1, No. 1, pp. 1-24 (2001).
Boger, D.L. et al., “Total Syntheses of Azafluoranthene Alkaloids: Rufescine and Imeluteine”, J. Org. Chem., vol. 49, No. 21, pp. 4050-4055 (1984).
Brancati, F.L. et al., “Body Weight Patterns from 20 to 49 Years of Age and Subsequent Risk for Diabetes Mellitus”, Arch. Intern. Med., vol. 159, pp. 957-963 (1999).
Bundgaard, H., Chapter 5: “Design and Application of Prodrugs”, A Textbook of Drug Design and Development, Harwood Academic Publishers, publ., Krogsgaard-Larsen, P. et al., eds., pp. 113-191 (1991).
Bundgaard, H., ed., Design of Prodrugs, Elsevier Science Publishers B.V., publ. (1985) (table of contents).
Butler, A.E. et al., “β-Cell Deficit and Increased β-Cell Apoptosis in Humans with Type 2 Diabetes”, Diabetes, vol. 52, pp. 102-110 (2003).
Chu, Z.-L. et al., “A Role for β-Cell-Expressed G Protein-Coupled Receptor 119 in Glycemic Control by Enhancing Glucose-Dependent Insulin Release”, Endocrinology, vol. 148, No. 6, pp. 2601-2609 (2007).
Cornicelli, J.A. et al., “15-Lipoxygenase and Its Inhibition: A Novel Therapeutic Target for Vascular Disease”, Current Pharmaceutical Design, vol. 5, No. 1, pp. 11-20 (1999).
Deng, H. et al., “Aryllead(IV) Reagents in Synthesis: Formation of the C11 Quaternary Center ofN-Methylwelwitindolinone C Isothiocyanate”, Organic Letters, vol. 3, No. 19, pp. 3001-3004 (2001).
Ford, E.S. et al., “Prevalence of the Metabolic Syndrome Among US Adults”, Journal of the American Medical Association, vol. 287, No. 3, pp. 356-359 (2002).
Fredriksson, R. et al., “Seven evolutionary conserved human rhodopsin G protein-coupled receptors lacking close relatives”, FEBS Letters, vol. 554, pp. 381-388 (2003).
Frlan, R. et al., “Recent Progress in Diaryl Ether Synthesis”, Synthesis, No. 14, pp. 2271-2285 (2006).
Gennaro, A.R., ed., Remington's Pharmaceutical Sciences, 17thEdition, Mack Publishing Company, publ., p. 1418 (1985).
Greene, T.W. et al., Protective Groups in Organic Synthesis, Second Edition, John Wiley & Sons, Inc., publ., pp. ix-x (table of contents) (1991).
Haning, H. et al., “Novel heterocyclic thyromimetics”, Bioorganic & Medicinal Chemistry Letters, vol. 15, pp. 1835-1840 (2005).
Hara, S., “Ileal Na+/bile acid cotransporter inhibitors”, Drugs of the Future, vol. 24, No. 4, pp. 425-430 (1999).
Hertzog, D.L., “Recent advances in the cannabinoids”, Expert Opin. Ther. Patents, vol. 14, No. 10, pp. 1435-1452 (2004).
Hill, J.O. et al., “Environmental Contributions to the Obesity Epidemic”, Science, vol. 280, pp. 1371-1374 (1998).
Hong, C.Y. et al., “Asymmetric Synthesis of Either Enantiomer of Opium Alkaloids and Morphinans. Total Synthesis of (−)- and (+)-Dihydrocodeinone and (−)- and (+)-Morphine”, J. Am. Chem. Soc., vol. 115, No. 23, pp. 11028-11029 (1993).
Itoh, T. et al., “A General Palladium-Catalyzed Coupling of Aryl Bromides/Triflates and Thiols”, Organic Letters, vol. 6, No. 24, pp. 4587-4590 (2004).
Jiang, G. et al., “Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1”, The Journal of Clinical Investigation, vol. 115, No. 4, pp. 1030-1038 (2005).
Justus, K. et al., “First Synthesis of a Strained 14-Membered Biaryl Ether Lactone by Macrolactonization”, Tetrahedron Letters, vol. 32, No. 14, pp. 5781-5784 (1991).
Katritzky, A.R. et al., “Efficient Transformations of Aldehydes and Ketones into One-Carbon Homologated Carboxylic Acids”, Synthesis, pp. 1425-1427 (1996).
Ketcha, D.M. et al., “The Reduction of N-(phenylsulfonyl)indoles with Sodium Cyanoborohydride in Trifluoroacetic Acid”, Tetrahedron Letters, vol. 30, No. 49, pp. 6833-6836 (1989).
Le Stunff, C. et al., “Early Changes in Postprandial Insulin Secretion, Not in Insulin Sensitivity, Characterize Juvenile Obesity”, Diabetes, vol. 43, pp. 696-702 (1994).
Magnus, P. et al., “Studies on the Synthesis of the Antitumor Agent CC-1065. Synthesis of the Unprotected Cyclopropapyrroloindole A Portion Using the 3,3′-Bipyrrole Strategy”, J. Am. Chem. Soc., vol. 109, No. 9, pp. 2706-2711 (1987).
NCBI Entrez Accession No. AAP72125 (gi:32165516), Fredriksson, R. et al., Dec. 8, 2003.
NCBI Entrez Accession No. AY288423 (gi:32165529), Fredriksson, R. et al., Dec. 8, 2003.
Nishio, T. et al., “Reduction of Indolin-2-ones and Desulfurization of Indoline-2-thiones to Indoline and Indole Derivatives”, Helvetica Chimica Acta, vol. 73, pp. 1719-1723 (1990).
Norman, M.H. et al., “Structure-Activity Relationships of a Series of Pyrrolo[3,2-d]pyrimidine Derivatives and Re
Fevig John M.
Wacker Dean A.
Bogie Terence J.
Bristol--Myers Squibb Company
Habte Kahsay T
LandOfFree
[6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4295712